Receptor selectivity

The receptor selectivity meaning is how narrowly a compound acts on its intended receptor instead of several, which is the usual explanation for fewer off-target effects. A selective agonist favors one target or response; “selective” does not mean exclusive, harmless, or guaranteed to stay selective at every concentration.

What does selective mean in a drug?

A selective drug produces a stronger effect at its intended receptor than at other possible targets. The selective agonist meaning is narrower still: an agonist switches a receptor on, while a selective agonist switches one target or response on more readily than others. Selectivity is a comparison, not an invisibility cloak; higher concentrations can narrow the gap.

For a receptor-selectivity peptide claim to mean much, the comparison needs a named target, measured response, and concentration. “Selective” by itself does not tell you how selective, compared with what, or whether the difference survives in people.

Why does receptor selectivity matter for peptides?

Receptor selectivity matters because extra targets or signals can create extra biology, including off-target effects. A compound that concentrates its activity on the wanted pathway may cause fewer unrelated effects than a broader compound. “May” is doing useful work there: cleaner lab pharmacology is not automatic proof of better outcomes or long-term safety.

That distinction matters across the growth-hormone peptide family, where a measured growth-hormone pulse is one endpoint and muscle gain, recovery, or safety are separate claims.

What does ipamorelin show about selectivity?

Ipamorelin shows both why selectivity is useful and why the evidence tier matters. Its foundational paper called it a selective growth-hormone secretagogue because, in rats and swine, ipamorelin released growth hormone without the ACTH and cortisol rise seen with GHRP-6 and GHRP-2. That direct comparison is animal-only, not a human head-to-head trial (Raun et al., 1998).

Human evidence supports the other half of the contrast. In 18 normal men, high-dose GHRP-6 raised prolactin and cortisol to about twice baseline (Bowers et al., 1990). The swine experiment, however, found no prolactin rise with any tested secretagogue, so it cannot prove that ipamorelin uniquely “spares” prolactin in people.

The honest read is specific: ipamorelin has animal evidence for cleaner hormonal selectivity, while GHRP-6 has human evidence for cortisol and prolactin spillover. There is no direct human ipamorelin-versus-GHRP-6 trial establishing fewer side effects. The ipamorelin profile therefore keeps sought-after benefits at mechanistic-hypothesis, rather than turning “selective” into “safer” or “human-proven.”

That is the practical receptor selectivity meaning: a comparative evidence claim, not a safety guarantee.